North America Point-of-Care (POC) Drug Abuse Testing Market – Industry Trends and Forecast to 2031

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

North America Point-of-Care (POC) Drug Abuse Testing Market – Industry Trends and Forecast to 2031

  • Pharmaceutical
  • Published Report
  • Sep 2024
  • North America
  • 350 Pages
  • No of Tables: 157
  • No of Figures: 50

North America Point Of Care Poc Drug Abuse Testing Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2024 –2031
Diagram Market Size (Base Year)
USD 558.70 Million
Diagram Market Size (Forecast Year)
USD 804.35 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America Point-of-Care (POC) Drug Abuse Testing Market, By Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) - Industry Trends and Forecast to 2031.

North America Point-of-Care (POC) Drug Abuse Testing Market

North America Point-of-Care (POC) Drug Abuse Testing Market Analysis and Size

The market is driven by increasing awareness and emphasis on drug abuse prevention and management, along with the growing need for quick and accurate drug testing in diverse environments. Key factors fueling market growth include rising drug abuse rates, stringent regulatory requirements for drug testing in workplaces, and advancements in POC testing technologies that offer enhanced accuracy and user convenience. Additionally, the growing prevalence of substance abuse disorders across different demographics contributes to the demand for effective and accessible drug testing solutions.

The North America Point-of-Care (POC) drug abuse testing market encompasses a range of diagnostic technologies and solutions designed to detect the presence of illicit substances or controlled drugs in an individual’s system at the location of care, rather than in a traditional laboratory setting. These tests provide rapid, on-the-spot results, which are crucial for timely decision-making and intervention in various settings such as medical facilities, emergency rooms, workplaces, and even in home settings. The market includes devices and testing kits for detecting drugs in urine, saliva, blood, and other biological samples.

Data Bridge Market Research analyzes that the North America Point-of-Care (POC) drug abuse testing market is expected to reach USD 804.35 million by 2031 from USD 558.70 million in 2023, growing with a CAGR of 4.8% in the forecast period of 2024 to 2031.

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable 2016-2021)

Quantitative Units

Revenue in USD Million

Segments Covered

Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others)

Countries Covered

U.S., Canada, Mexico

Market Players Covered

Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., Bio-rad Laboratories, inc., Agilent Technologies, Advacare Pharma, Cliawaived inc. among others.

Market Definition

Point-of-Care (PoC) drug abuse testing refers to rapid screening methods used to detect the presence of drugs or their metabolites in a person's system at the site of care, such as clinics or emergency rooms. These tests provide quick results, enabling timely decision-making for treatment or intervention. Typically involving urine, saliva, or blood samples, PoC testing is essential for monitoring substance use, ensuring patient safety, and facilitating access to appropriate support services

North America Point-of-Care (POC) drug abuse testing market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

  • Rising Incidence of Drug Abuse

Drug abuse involving opiates, cannabinoids, and amphetamines has been growing regionally, creating a public health crisis that requires immediate and scalable solutions. Healthcare providers, law enforcement agencies, and employers are increasingly relying on POC drug testing as it offers rapid, accurate, and on-site detection, which is critical in managing the consequences of drug abuse.

In healthcare, the need for quick detection of drug abuse is essential to offer timely interventions, especially in emergency cases or rehabilitation centers. In law enforcement, the ability to test individuals on-site accelerates decision-making and enhances efforts to curb drug-related crimes. Similarly, workplaces are adopting POC drug testing to maintain a drug-free environment, reduce liability, and comply with safety regulations.

Technological advancements in POC testing devices further support the growing demand for rapid, reliable testing methods. These devices are becoming more portable, user-friendly, and capable of detecting a wide range of substances, making them ideal for use in non-laboratory settings.

For instance,

  • In January 2024, according to an article published by NCBI, Opioid Use Disorder (OUD) affects over 16 million people worldwide, including 2.1 million in the U.S., leading to more than 120,000 deaths regionally each year. The prevalence of opioid use and dependency is high, with up to 50% of long-term opioid users meeting OUD criteria. The rising incidence of opioid-related issues drives the need for effective drug testing solutions, thereby fuelling growth in the North America Point-of-Care (POC) drug abuse testing market
  • In August 2023, according to an article published by WHO, in 2019, approximately 600,000 deaths regionally were linked to drug use, with about 80% related to opioids. Of these, around 125,000 were due to opioid overdose, while non-fatal overdoses are significantly more common. The rise in opioid overdoses is attributed to increased opioid availability for chronic pain management and the presence of potent opioids on the illicit market. In the USA, drug overdose deaths totaled 70,630 in 2019, with synthetic opioids involved in about half of these cases.

Growth in Home and Parental Drug Testing Kits

The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.

Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.

Increased awareness of substance abuse and the easy availability of these kits through pharmacies and online platforms are contributing to market growth. The trend is further supported by a growing preference for non-invasive sample collection methods, such as saliva or urine tests, which are simple to use at home.

For instance,

  • In November 2023, according to an article published by DNA Forensics Laboratory Pvt. Ltd., in recent years, at-home drug testing kits have become increasingly popular due to their convenience and ease of access. These kits enable individuals to conduct drug tests privately at home, typically including test strips or collection devices along with clear instructions for sample collection and result interpretation. This trend towards home testing highlights the "growth in home and parental drug testing kits" and drives the demand for such products. The growing preference for private and convenient drug testing solutions propels the expansion of the North America Point-of-Care (POC) drug abuse testing market.

In conclusion, the rising demand for home and parental drug testing kits is driving significant growth in the POC drug abuse testing market by offering consumers private, convenient, and reliable options for substance abuse monitoring, fueling expansion in this segment.

Opportunity

  • Growing Awareness and the Campaign for Drug Testing

The increasing awareness surrounding the dangers of drug abuse, coupled with robust public health campaigns and government support, presents a significant opportunity for growth in the North America Point-of-Care (POC) drug abuse testing market. As society becomes more cognizant of the detrimental impacts of substance abuse, there is a growing demand for accessible and effective testing solutions. Public health campaigns, often spearheaded by governmental and non-governmental organizations, play a crucial role in educating communities about the importance of early detection and intervention. These initiatives not only amplify the visibility of drug abuse issues but also advocate for the use of point-of-care testing as a preventive measure. Furthermore, government support through funding and policy-making enhances the accessibility of POC drug testing solutions by promoting regulatory frameworks that facilitate the adoption of these technologies in various settings, including workplaces, schools, and public health programs. The combination of heightened awareness and strategic support fosters an environment conducive to market expansion, driving innovation and increasing the availability of advanced testing solutions to address the evolving needs of society.

  • In December 2023, according to the article published by the Greater London Authority, UK government allocated USD 1.54 million to this mission, focusing on testing for 14 different drugs with the rising awareness and proactive government initiatives in the UK have led to the implementation of random mandatory drug testing for individuals released from prison, aiming to reduce crime rates. This move underscores the nation's commitment to tackling substance abuse and its impact on criminal behavior, reflecting broader efforts to enhance public safety and well-being.
  • In July 2021, according to the article published by Commonwealth of Australia and the Department of Health and Aged Care, the Australian government launched the National Ice Action Strategy, which included significant investments to enhance Point-of-Care (POC) drug abuse testing. This initiative aimed to curb the growing use of methamphetamines, commonly known as "ice," by providing law enforcement and healthcare providers with more accessible and accurate drug testing tools. The strategy also focused on expanding the availability of POC testing in remote and rural areas, ensuring that communities across the country could benefit from timely and effective drug detection and intervention measures.

Hence, the convergence of growing awareness, active public health campaigns, and strong government support is poised to significantly benefit the North America Point-of-Care (POC) drug abuse testing market. This dynamic environment not only promotes the adoption of drug testing technologies but also encourages the development of more sophisticated and accessible solutions. As these factors continue, the future of POC drug abuse testing looks promising, with enhanced opportunities for innovation, broader market reach, and improved public health outcomes.

Restraint/Challenge

  • High Costs Associated with the Testing

The complexity of developing reliable and accurate POC drug abuse tests often requires advanced technology, specialized materials, and rigorous validation processes, all of which contribute to elevated production costs. These costs are further compounded by stringent regulatory requirements, as ensuring compliance with international standards demands extensive testing, quality control, and documentation, adding to the overall expense. Additionally, the need for consistent research and development to keep pace with emerging drug abuse patterns and to enhance the sensitivity and specificity of these tests drives up the costs even more. For healthcare providers, the high upfront investment required to integrate these testing solutions into their practices can be prohibitive, particularly for smaller clinics or organizations with limited budgets. This financial burden can deter the adoption of POC drug abuse testing despite its potential benefits in terms of speed and convenience. The situation is exacerbated in low- and middle-income countries, where healthcare budgets are already strained, and the added cost of POC testing can be a barrier to implementation, limiting the market's expansion into these regions. Moreover, the high cost can lead to disparities in healthcare access, as only well-funded institutions may be able to afford these advanced testing methods, leaving vulnerable populations without adequate testing and care. This challenge is not only a financial one but also an ethical issue, as the inability to provide affordable testing solutions undermines the efforts to combat drug abuse on a broader scale.

 For instance,

  • In May 2023, according to an article published by the National Library of Medicine, POC testing was costlier performed on an individual basis when compared to traditional laboratory testing due to the single-use nature of most POCT devices, which adds to the overall expenses
  • In January 2024, according to an article published by Checkr., the cost of drug testing for comprehensive laboratory panels can exceed USD 500. Onsite tests typically range from USD 20 to USD 40, but the need for lab confirmation can drive prices up, starting at USD 50 and varying based on the test type and substances screened. High volumes of tests might reduce the average cost per test, but the overall expense can still be substantial

Hence, the high cost of POC drug abuse testing creates significant barriers to its broader adoption, limiting accessibility, especially in resource-constrained regions. This financial challenge not only hampers market growth but also exacerbates healthcare inequalities, preventing many from receiving timely and effective drug abuse testing, and is expected to act as a challenge for market growth in the future.

Recent Developments

  • In August 2024, Abbott announced a North America partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre Continuous Glucose Monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed
  • In March 2024, Abbott extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-2027 season, continuing as their North America health sciences and nutrition partner. Since 2021, Abbott provided over 25,000 hours of nutrition education and screened more than 3,000 children for malnutrition
  • In August 2023, SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities. The partnership with SSM Health benefits Siemens Healthineers by expanding its market presence, increasing visibility of its technology, fostering long-term growth, and enhancing its reputation in the healthcare sector
  • In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
  • In November 2023, Roche launched next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges. Roche’s next-generation qPCR system boosts its market position, meets clinical and public health needs, and opens new revenue opportunities while showcasing its commitment to innovation

North America Point-of-Care (POC) drug abuse testing market Scope

The North America Point-of-Care (POC) drug abuse testing market is segmented into eight notable segments based on drug type, products, prescription, sample type, testing type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Drug Type

  • Amphetamines
  •  Opiates
  •  Cannabinoids
  •  Cocaine
  •  Barbiturates
  •  Benzodiazepines
  •  Methadone
  •  Phencyclidine
  •  Tricyclic Antidepressants
  •  Others

On the basis of drug type, the market is segmented into amphetamines, cannabinoids, opiates, cocaine, benzodiazepines, barbiturates, phencyclidine, methadone, tricyclic antidepressants, and others.

Products

  • Devices
  • Consumables and Accessories

On the basis of products, the market is segmented into devices and consumables and accessories.

Prescription

  • Over the Counter Testing
  • Prescription-Based Testing

On the basis of prescription mode, the market is segmented into prescription-based testing, and over the counter testing.

Sample Type

  • Urine
  •  Saliva
  •  Blood
  •  Hair
  •  Breath
  •  Others

On the basis of sample type, the market is segmented into urine, saliva, blood, hair, breath, and others.

Testing Type

  • Random Testing
  •  Post-Incident Testing
  •  Abstinence Testing

On the basis of testing type, the market is segmented into random testing, post-incident testing, and abstinence testing.

Application

  • Medical Screening
  •  Workplace Screening
  •  Law Enforcement and Criminal Justice
  •  Pain Management
  •  Substance Abuse Treatment and Rehabilitation
  •  Parental or Home Drug Testing
  •  Sports and Athletics Testing
  •  Drug Screening in Schools and Educational Institutions
  •  Others

On the basis of application, the market is segmented medical screening, workplace screening, law enforcement and criminal justice, pain management, substance abuse treatment and rehabilitation, parental or home drug testing, sports and athletics testing, drug screening in schools and educational institutions, and others.

End User

  • Healthcare Facilities
  •  Employers
  •  Government Institutes
  •  Others

On the basis of end user, the market is segmented into healthcare facilities, employers, government institute, and others.

Distribution Channel

  • Direct Tender
  •  Retail Sales
  •  Others

On the basis of distribution channel, the market is segmented into direct tender, retails sales, and others.

North America Point-of-Care (POC) Drug Abuse Testing Market Regional Analysis/Insights

North America Point-of-Care (POC) drug abuse testing market is analyzed, and market size insights and trends are provided by based on drug type, products, prescription, sample type, testing type, application, end user, distribution channel as referenced above.

The countries covered in this market report are U.S., Canada, and Mexico.

The U.S. is expected to dominate in the North America market due to factors such as large population, high healthcare expenditure, sophisticated healthcare system, extensive pharmaceutical industry, and widespread consumer awareness and access to cold sore treatments.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and North America Point-of-Care (POC) Drug Abuse Testing Market Share Analysis

The North America Point-of-Care (POC) drug abuse testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the North America Point-of-Care (POC) drug abuse testing market.

Some of the major players operating in the North America Point-of-Care (POC) drug abuse testing market are Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., Bio-rad Laboratories, inc., Agilent Technologies, Advacare Pharma, and Cliawaived inc. among others.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS FIVE FORCES ANALYSIS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISING INCIDENCE OF DRUG ABUSE

5.1.2 GROWING EMPHASIS ON WORKPLACE SAFETY

5.1.3 GROWTH IN HOME AND PARENTAL DRUG TESTING KITS

5.1.4 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES

5.2 RESTRAINTS

5.2.1 DATA SECURITY AND PRIVACY CONCERNS

5.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES

5.3 OPPORTUNITIES

5.3.1 GROWING AWARENESS AND THE CAMPAIGN FOR DRUG TESTING

5.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS

5.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE DRUG ABUSE TESTING

5.4 CHALLENGES

5.4.1 LIMITED AWARENESS AND ACCEPTANCE

5.4.2 HIGH COSTS ASSOCIATED WITH THE TESTING

6 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE

6.1 OVERVIEW

6.2 AMPHETAMINES

6.3 OPIATES

6.4 CANNABINOIDS

6.5 COCAINE

6.6 BARBITURATES

6.7 BENZODIAZEPINES

6.8 METHADONE

6.9 PHENCYCLIDINE

6.1 TRICYCLIC ANTIDEPRESSANTS

6.11 OTHERS

7 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS

7.1 OVERVIEW

7.2 DEVICES

7.2.1 ANALYZER

7.2.1.1 IMMUNOASSAY ANALYZER

7.2.1.1.1 HIGH VOLUME

7.2.1.1.2 MID VOLUME

7.2.1.1.3 LOW VOLUME

7.2.1.2 BREATHALYZER

7.2.1.2.1 ELECTROCHEMICAL FUEL CELL BREATH ANALYZERS

7.2.1.2.2 INFRARED OPTICAL SENSOR BREATH ANALYZERS

7.2.1.2.3 SEMICONDUCTOR BREATH ANALYZERS

7.2.2 RAPID DEVICES

7.2.3 DRUG TESTING CASSETTE

7.2.4 DRUG TESTING CUPS

7.2.5 DIP CARDS/STRIPS

7.2.6 ORAL FLUID TESTING DEVICES

7.2.7 OTHERS

7.2.8 MODALITY

7.2.9 HANDHELD

7.2.10 MOBILE

7.2.11 MANUAL

7.2.12 AUTOMATED

7.3 CONSUMABLES AND ACCESSORIES

7.3.1 ASSAY KITS AND REAGENTS

7.3.2 PROBES

7.3.3 OTHERS

7.3.3.1 DAST-10

7.3.3.2 Plasma Protein Binding

7.3.3.3 Plasma and Serum Stability

7.3.3.4 Others

7.3.3.4.1 Multi-Panel Drug Test Kits

7.3.3.4.2 Single-Panel Drug Test Kits

8 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION

8.1 OVERVIEW

8.2 OVER THE COUNTER TESTING

8.3 PRESCRIPTION-BASED TESTING

9 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE

9.1 OVERVIEW

9.2 URINE

9.3 SALIVA

9.4 BLOOD

9.5 HAIR

9.6 BREATH

9.7 OTHERS

10 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE

10.1 OVERVIEW

10.2 RANDOM TESTING

10.3 POST-INCIDENT TESTING

10.4 ABSTINENCE TESTING

11 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 MEDICAL SCREENING

11.3 WORKPLACE SCREENING

11.4 LAW ENFORCEMENT AND CRIMINAL JUSTICE

11.5 PAIN MANAGEMENT

11.6 SUBSTANCE ABUSE TREATMENT AND REHABILITATION

11.7 PARENTAL OR HOME DRUG TESTING

11.8 SPORTS AND ATHLETICS TESTING

11.9 DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS

11.1 OTHERS

12 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER

12.1 OVERVIEW

12.2 HEALTHCARE FACILITIES

12.2.1 HOSPITALS

12.2.2 EMERGENCY DEPARTMENT

12.2.3 CENTRAL LABS

12.2.4 CLINICS

12.2.5 POISON CONTROL CENTERS

12.2.6 OTHERS

12.3 EMPLOYERS

12.4 GOVERNMENT INSTITUTES

12.5 OTHERS

13 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

13.4 OTHERS

14 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 CANADA

14.1.3 MEXICO

15 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 ABBOTT LABORATORIES

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 SIEMENS HEALTHINEERS AG

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENTS

17.3 QUEST DIAGNOSTICS INCORPORATED

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 THERMO FISHER SCIENTIFIC INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 F.HOFFMAN-LA ROCHE LTD.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT UPDATES

17.5.6 RECENT UPDATES

17.6 ACCUBIOTECH CO., LTD.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 ADVACARE PHARMA

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT UPDATES

17.8 AGILENT TECHNOLOGIES, INC

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT UPDATES

17.9 ASSURE TECH (HANGZHOU) CO., LTD.

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 BD

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 BEIJING HOTGEN BIOTECHN CO., LTD.

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENT

17.12 BIOEASY BIOTECHNOLOGY CO., LTD.,

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.13 BIO-RAD LABORATORIES, INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 CLIAWAIVED, INC.

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 DRUGSCAN

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 EGENS GROUP (NANTONG YISHI BIOTECHNOLOGY CO., LTD.)

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 HANGZHOU ALLTEST BIOTECH CO.,LTD

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 JOYSBIO (TIANJIN) BIOTECHNOLOGY CO., LTD

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT UPDATES

17.19 LIFESIGN LLC.

17.19.1 COMPANY SNAPSHOT

17.19.2 PRODUCT PORTFOLIO

17.19.3 RECENT DEVELOPMENT

17.2 MERCK KGAA

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENTS

17.21 MP BIOMEDICALS

17.21.1 COMPANY SNAPSHOT

17.21.2 PRODUCT PORTFOLIO

17.21.3 RECENT DEVELOPMENT

17.22 PREMIER BIOTECH, INC.

17.22.1 COMPANY SNAPSHOT

17.22.2 PRODUCT PORTFOLIO

17.22.3 RECENT DEVELOPMENT

17.23 SYSMEX CORPORATION

17.23.1 COMPANY SNAPSHOT

17.23.2 REVENUE ANALYSIS

17.23.3 PRODUCT PORTFOLIO

17.23.4 RECENT DEVELOPMENTS

17.24 WONDFO

17.24.1 COMPANY SNAPSHOT

17.24.2 PRODUCT PORTFOLIO

17.24.3 RECENT DEVELOPMENT

17.25 XIAMEN BOSON BIOTECH CO., LTD.

17.25.1 COMPANY SNAPSHOT

17.25.2 PRODUCT PORTFOLIO

17.25.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 2 NORTH AMERICA AMPHETAMINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 3 NORTH AMERICA OPIATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 4 NORTH AMERICA CANNABINOIDS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 5 NORTH AMERICA COCAINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 6 NORTH AMERICA BARBITURATES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 7 NORTH AMERICA BENZODIAZEPINES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 8 NORTH AMERICA METHADONE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 9 NORTH AMERICA PHENCYCLIDINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 10 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 11 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 12 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)

TABLE 13 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 14 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 16 NORTH AMERICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 17 NORTH AMERICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 18 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 19 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 20 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 21 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)

TABLE 22 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 23 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 24 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 25 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)

TABLE 26 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 27 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)

TABLE 28 NORTH AMERICA OVER THE COUNTER TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 29 NORTH AMERICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 30 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)

TABLE 31 NORTH AMERICA URINE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 32 NORTH AMERICA SALIVA IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 33 NORTH AMERICA BLOOD IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 34 NORTH AMERICA HAIR IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 35 NORTH AMERICA BREATH IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 36 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 37 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)

TABLE 38 NORTH AMERICA RANDOM TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 39 NORTH AMERICA POST-INCIDENT TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 40 NORTH AMERICA ABSTINENCE TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 41 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 42 NORTH AMERICA MEDICAL SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 43 NORTH AMERICA WORKPLACE SCREENING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 44 NORTH AMERICA LAW ENFORCEMENT AND CRIMINAL JUSTICE IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 45 NORTH AMERICA PAIN MANAGEMENT IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 46 NORTH AMERICA SUBSTANCE ABUSE TREATMENT AND REHABILITATION IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 47 NORTH AMERICA PARENTAL OR HOME DRUG TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 48 NORTH AMERICA SPORTS AND ATHLETICS TESTING IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 49 NORTH AMERICA DRUG SCREENING IN SCHOOLS AND EDUCATIONAL INSTITUTIONS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 50 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 51 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 52 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 53 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 NORTH AMERICA EMPLOYERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 55 NORTH AMERICA GOVERNMENT INSTITUTES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 56 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 57 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 58 NORTH AMERICA DIRECT TENDER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 59 NORTH AMERICA RETAIL SALES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 60 NORTH AMERICA OTHERS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY REGION, 2022-2031 (USD THOUSAND)

TABLE 61 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 62 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 63 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)

TABLE 64 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 66 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 67 NORTH AMERICA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 68 NORTH AMERICA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 70 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 71 NORTH AMERICA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 72 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 73 NORTH AMERICA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)

TABLE 74 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 75 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)

TABLE 77 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)

TABLE 78 NORTH AMERICA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 79 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)

TABLE 80 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)

TABLE 81 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)

TABLE 82 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 83 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 84 NORTH AMERICA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 86 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 87 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)

TABLE 88 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 89 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 90 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 91 U.S. ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 92 U.S. IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 94 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 95 U.S. BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 96 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 97 U.S. DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)

TABLE 98 U.S. CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 99 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 100 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)

TABLE 101 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)

TABLE 102 U.S. ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 103 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)

TABLE 104 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)

TABLE 106 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 107 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 108 U.S. HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 109 U.S. POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 110 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)

TABLE 112 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 113 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 114 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 115 CANADA ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 116 CANADA IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 117 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 119 CANADA BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 120 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 121 CANADA DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)

TABLE 122 CANADA CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)

TABLE 125 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)

TABLE 126 CANADA ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 127 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)

TABLE 128 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)

TABLE 129 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)

TABLE 130 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 131 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 132 CANADA HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 133 CANADA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 134 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRODUCTS, 2022-2031 (USD THOUSAND)

TABLE 136 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 138 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 139 MEXICO ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 140 MEXICO IMMUNOASSAY ANALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 141 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 142 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 143 MEXICO BREATHALYZER IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 144 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 145 MEXICO DEVICES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODE, 2022-2031 (USD THOUSAND)

TABLE 146 MEXICO CONSUMABLES AND ACCESSORIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 147 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND)

TABLE 148 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (VOLUME)

TABLE 149 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TEST TYPE, 2022-2031 (ASP)

TABLE 150 MEXICO ASSAY KITS AND REAGENTS IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY MODALITY, 2022-2031 (USD THOUSAND)

TABLE 151 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY PRESCRIPTION, 2022-2031 (USD THOUSAND)

TABLE 152 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY SAMPLE TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TESTING TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY APPLICATION, 2022-2031 (USD THOUSAND)

TABLE 155 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 156 MEXICO HEALTHCARE FACILITIES IN POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 157 MEXICO POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

List of Figure

FIGURE 1 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: END USER COVERAGE GRID

FIGURE 8 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SEGMENTATION

FIGURE 11 TEN SEGMENTS COMPRISE THE NORTH AMERICA POINT-OF-CARE DRUG ABUSE TESTING MARKET, BY DRUG TYPE

FIGURE 12 EXECUTIVE SUMMARY

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 RISING INCIDENCE OF DRUG ABUSE IS DRIVING THE GROWTH OF THE NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET FROM 2024 TO 2031

FIGURE 15 THE AMPHETAMINES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOB POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET IN 2024 AND 2031

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET

FIGURE 17 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2023

FIGURE 18 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 19 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 20 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS 2023

FIGURE 22 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, 2024-2031 (USD THOUSAND)

FIGURE 23 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, CAGR (2024-2031)

FIGURE 24 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 25 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2023

FIGURE 26 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, 2024-2031 (USD THOUSAND)

FIGURE 27 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, CAGR (2024-2031)

FIGURE 28 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY PRESCRIPTION, LIFELINE CURVE

FIGURE 29 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2023

FIGURE 30 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, 2024-2031 (USD THOUSAND)

FIGURE 31 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, CAGR (2024-2031)

FIGURE 32 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 33 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2023

FIGURE 34 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, 2024-2031 (USD THOUSAND)

FIGURE 35 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, CAGR (2024-2031)

FIGURE 36 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY TESTING TYPE, LIFELINE CURVE

FIGURE 37 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2023

FIGURE 38 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, 2024-2031 (USD THOUSAND)

FIGURE 39 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, CAGR (2024-2031)

FIGURE 40 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 41 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2023

FIGURE 42 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 43 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, CAGR (2024-2031)

FIGURE 44 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY END USER, LIFELINE CURVE

FIGURE 45 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 46 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 47 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 48 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 49 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: SNAPSHOT (2023)

FIGURE 50 NORTH AMERICA POINT-OF-CARE (POC) DRUG ABUSE TESTING MARKET: COMPANY SHARE 2023 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on North America Point-of-Care (POC) Drug Abuse Testing Market, By Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) - Industry Trends and Forecast to 2031. .
The North America Point Of Care Poc Drug Abuse Testing Market size was valued at USD 558.70 USD Million in 2023.
The North America Point Of Care Poc Drug Abuse Testing Market is projected to grow at a CAGR of 4.8% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada, Mexico.